As the pharmaceutical development world becomes smaller and smaller, there are a number of major trends that are well established and under considerable discussion. This paper explores five important trends in pharmaceutical development that have not yet been considered fully, although certainly none of them are unfamiliar: (1) surrogate endpoints/mortality endpoints; (2) individualization of therapy/dose response; (3) examination of underlying data; (4) growing internalization of drug development and evaluation; and (5) the impact of forces other than regulators on product use and development.
EchtDSLiebsonPRMitchellLBMortality and morbidity in patients receiving encainide, flecainide, or placebo. N Engl J Med. 1991;324: 781–788.
2.
PackerMCarverJRRodehefferRTEffect of oral milronine on mortality in severe chronic heart failure. N Engl J Med. 1991;325: 1468–1475.
3.
Gruppo Italiano per lo Studio Della Sopravvivenza Nell’ Infarcto Miocardico.GISSI-2: A factoral randomized trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Lancet. 1990;336: 65–71.
4.
The International Study Group.In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomized between alteplase and streptokinase with or without heparin. Lancet. 1900;336: 71–75.
5.
BraunwaldWEKnatterudGLPassamaniERRobertsonTL. Announcement of protocol change in thrombolysis in myocardial infarction trial (letter). J Am Coll Cardiol. 1987;9: 467.
6.
BergstromRFPeytonALLembergerL.Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction. Clin Pharmacol Ther. 1992;51: 239–248.
7.
KalowW.Genetic polymorphism in drug oxidation. In: DahlSGGramLF, ed. Clinical Pharmacology in Psychiatry. (Psychopharmacology Series 7). Berlin, Heidelberg: Springer-Verlag: 1989.
8.
ShahRROatesNSIdleJRSmithRLLockhartJDF. Impaired oxidation of debrisoquine in patients with perhexilene neuropathy. Brit Med J. 1982;284: 295–299.
9.
OatesNSShahRRIdleJRSmithRL. Influence of oxidation polymorphism on phenformin kinetics and dynamics. Clin Pharmacol Ther. 1983;34: 827–834.
10.
WiholmBEAlvanGBertilssonLSaweJSjoqvistF.Hydroxylation of debrisoquine in patients with lactic acidosis after phenformin. (letter). Lancet. 1981;1: 1098–1099.
11.
CooperIGEvansDAP. Oxidation polymorphism has clinical relevance. Lancet. 1984;2: 227.
